
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the...

German antibodies in demand in USA
Initially, Seattle-based Just - Evotec Biologics will receive US$28.6m from the Defense Health Agency ("DHA") under a partnership announced...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

German Health Ministry to invest €6.2bn in vaccines
With the request to the national budget committee, which will decide on it tomorrow, Germany more than doubles the amount of money to be invested...

Janssen presents one-shot COVID-19 vaccine data
Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...